EFPIA-VE立场文件欧盟CVH计划

EFPIA & Vaccines Europe position paper September 2025 EU Cardiovascular Health Plan – EFPIA & Vaccines Europe position paper Introduction With more than 13 million new cases diagnosed annually1and costs amounting to €282billion2each year, the burden of Cardiovascular Disease (CVD)3on patients, healthcare systems,and society at large is staggering. One in three deaths in the EU are due to CVD, 20% of allpremature deaths (before the age of 65) are caused by cardiovascular conditions, making it thenumber one killer in Europe. To effectively address this pressing public health issue, robust action on improving cardiovascular health is needed at all levels,that not only focuses on reducing premature and preventable deaths, but also fosters innovation, equity, and resilience inhealthcare. Prevention, early detection, timely intervention and long term, person-centred management, are essential forimproving health outcomes and quality of life for patients, as well as continued research and development to address unmethealth needs. EFPIA and Vaccines Europe welcomes the forthcoming EU Cardiovascular Health (CVH) Plan which will deliver much-neededpolitical momentum for a renewed and coordinated effort to improve cardiovascular health in Europe. The plan should set outimpactful, high-level targets and actions focused on reducing premature mortality and morbidity with clear added value whichcan be developed and implemented with all stakeholders, including patients, healthcare professionals and industry. The pharmaceutical industry has greatly contributed to the improvement of healthcare and health outcomes during the lastnumber of decades, including for people living with cardiovascular disease. The life sciences sector brings extensive experience intranslating scientific discovery into tangible health solutions that benefit patients and society - leveraging this expertise representsan asset and will be vital for building resilient health systems capable of addressing current and future cardiovascular challenges. 1European Society of Cardiology (2020) Fighting cardiovascular disease – a blueprint for EU action2Luengo-Fernandez et al., (2023), Economic burden of cardiovascular diseases in the European Union: a population-based cost study.https://academic.oup.com/eurheartj/article/44/45/4752/72512393Cardiovascular disease (CVD) is a group of conditions affecting the heart or blood vessel - they include heart attacks and strokes, as well as arrhythmias and congenital heart disease. It remains the leading causeof death across Europe, one in every three deaths are caused by CVD. The burden of CVD in the EU EU Cardiovascular Health Plan – EFPIA & Vaccines Europe position paper Scope and ambition of anEU Cardiovascular Health Plan EFPIA and Vaccines Europe supports arobustandwell-resourcedEU CVH Plan as complement to ahorizontal approach to tackling Non-Communicable Diseases (NCDs). The EU CVH Plan should set outactions withclear added valuewhich can complement and create synergies between Member Statenational policies, and include clear objectives andmeasurable targets, for example by aiming for thereduction of CVD premature and preventable death by one third by 2030, in alignment with the UNSustainable Development Goal 3.4.4 The plan should embrace a comprehensive approach to primary, secondary and tertiary prevention,care and rehabilitation. The primary objective should be topush back the morbidity curveby focusing onearly detectionyears before the clinical manifestation of disease. This can beachieved by taking an evidence-based, people-centred andproactive approach to preventionofcardiovascular disease, aligning with the latest scientific advances and clinical guidelines and takinginto account major modifiable risk factors, including LDL-C, hypertension, atrial fibrillation and alsoconditions such as chronic kidney disease, thyroid disorders, obesity and diabetes - diseases whichsignificantly contribute to the course and prognosis of CVD, but remain sub-optimally managed. Learning from the successes of the Europe’s Beating Cancer Plan, the EU CVH Plan should at itsheart placereduction of disparitiesin access to prevention, diagnosis and treatment, and healthoutcomes, across different population groups with particular attention to removing inequities basedon gender, socioeconomic factors and place of living.5Achieving equitable access that improvesoutcomes for all population groups, should guide the spirit of the EU CVH Plan. Furthermore, the plan should support continuedresearch and innovationto further improve healthoutcomes across CVDs and cater to unmet health needs, while also contributing to a vital Europeanresearch eco-system and competitiveness. The design and implementation of the EU CVH Plan should build onexperiences and good practicefrom the Europe’s Beating Cancer Plan - including the need for a goal-driven and whole-diseasecontinuum approach - and be executed incollaboration with all stakehol